NCT07829744Not yet recruitingPhase 2
Perioperative Targeted Therapy in Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer With Rare Driver Mutations
Source: ClinicalTrials.gov · Last updated 21 Sept 2026
Brief summary (registry, in English)
This study evaluates the effectiveness and safety of targeted therapy given before and after surgery in patients with resectable or potentially resectable stage III non-small cell lung cancer with selected genetic alterations. Treatment is assigned according to tumor genetic findings.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 190 (estimated)
- First submitted
- 15 Sept 2026
- Start date
- 20 Sept 2026
- Primary completion date
- 30 Jun 2030
- Lead sponsor
- Shanghai Zhongshan Hospital
- Diseases
- Lung cancer
- NCT number
- NCT07829744
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 190
- From 20 Sept 2026 to the primary completion date, 30 Jun 2030
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Stage III NSCLC considered unresectable by surgical assessment.
- Lung cancer treatment within the previous 2 years, or prior lung cancer with a remission duration of less than 2 years.
- Another malignancy within the previous 5 years.
- Major surgery within 28 days before the first study dose.
- Any contraindication to the assigned targeted therapy.
Other
- Inability or unwillingness to provide informed consent or comply with study requirements.
Who the study is looking for
- Age ≥18 years.
- Histologically or cytologically confirmed stage III NSCLC (AJCC 8th edition), considered resectable or potentially resectable.
- Documented EGFR exon 20 insertion, ALK fusion, ROS1 fusion, MET exon 14 skipping alteration, RET fusion, or KRAS G12C mutation.
- At least one measurable lesion per RECIST 1.1 and ECOG performance status 0-1.
- Adequate cardiopulmonary and major organ function for surgery.
- Written informed consent and willingness to comply with study procedures, sample collection, and follow-up.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.